tert-butyl N-[(2R)-1-hydroxy-3-phenylmethoxypropan-2-yl]carbamate

We are tert-butyl N-[(2R)-1-hydroxy-3-phenylmethoxypropan-2-yl]carbamate CAS:120349-75-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  tert-butyl N-[(2R)-1-hydroxy-3-phenylmethoxypropan-2-yl]carbamate
CAS.NO:120349-75-9
Molecular Formula: C15H23NO4
Molecular Weight: 281.34700

Synonyms:
tert-butyl N-[(2R)-1-hydroxy-3-phenylmethoxypropan-2-yl]carbamate

Physical and Chemical Properties:
Density: /
Boiling point: /
Melting point: 66-69ºC (lit.)
Flash point: /
Refractive index: /

Specification:
Appearance: White or Off-white Solid
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:Pharmaceutical intermediates.

Related News: Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association.dehydroepiandrosterone Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association.2- (2-metoxietoxi) -N- (oxometilideno) CAS:89020-61-1 Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association.2-methylpyridine Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.